GLSI — Recent News Coverage
All news mentioning GLSI in ESEN's AI-graded feed
News stories with GLSI as an affected ticker. Each article is graded by ESEN AI for impact level and direction (up/down/flat) on GLSI. See /coverage/GLSI for the 30-day aggregate.
RTTNEWS.COM
·
2026-11-17
NEUTRAL
BULLISH
CORR0.55
Greenwich LifeSciences Stock Up 23% On Immunotherapy Trial Update
$GLSI
◈ ESEN AI
GLSI gained 23% following the acceptance of two abstracts from its Phase III FLAMINGO-01 trial for publication at the 2026 San Antonio Breast Cancer Symposium. This represents meaningful clinical validation for the comp…
MANILATIMES.NET
·
2026-11-17
LOW
NEUTRAL
CORR0.15
Greenwich LifeSciences Announces Acceptance of Abstracts at SABCS 2026
$GLSI
◈ ESEN AI
GLSI announced acceptance of two abstracts for presentation at the San Antonio Breast Cancer Symposium (SABCS) 2026, a scheduled conference disclosure. This is a procedural milestone in the clinical trial communication …
RTTNEWS.COM
·
2026-08-10
LOW
NEUTRAL
CORR0.15
Greenwich LifeSciences Stock Gains 4% After Extending Share Lock-Up
$GLSI
◈ ESEN AI
GLSI shares rallied 4.5% following a board announcement to extend the lock-up period for insiders and pre-IPO investors through January 31, 2027. This procedural disclosure is a routine governance action that signals ma…
MANILATIMES.NET
·
2026-07-22
NEUTRAL
BULLISH
CORR0.42
Greenwich LifeSciences Announces Approval to Expand FLAMINGO-01 into the United Kingdom
$GLSI
◈ ESEN AI
Greenwich LifeSciences (GLSI) has secured regulatory clearance to expand its Phase III FLAMINGO-01 trial into the United Kingdom, broadening the geographic footprint for its breast cancer recurrence immunotherapy candid…
MANILATIMES.NET
·
2026-07-20
NEUTRAL
NEUTRAL
CORR0.15
Greenwich LifeSciences Provides Clinical Updates on FLAMINGO-01
$GLSI
◈ ESEN AI
GLSI announced routine clinical updates on FLAMINGO-01, its Phase III trial evaluating GLSI-100, an immunotherapy candidate for breast cancer recurrence prevention. The company is a clinical-stage biotech with limited c…
SEEKINGALPHA.COM
·
2026-07-16
LOW
BULLISH
CORR0.35
Greenwich LifeSciences The Overlooked Need (NASDAQ:GLSI)
$GLSI
◈ ESEN AI
GLSI represents a concentrated single-asset biotech thesis centered on GLSI-100, a clinical-stage immunotherapy targeting HER2-positive breast cancer. The article frames this as an overlooked opportunity, suggesting mar…
MARKETS.BUSINESSINSIDER.COM
·
2026-07-09
HIGH
BULLISH
CORR0.72
Greenwich LifeSciences Announces European Approval for Use of Commercially Manufactured GP2 in FLAMINGO-01
$GLSI
◈ ESEN AI
Greenwich LifeSciences (GLSI) achieved a significant regulatory milestone with European approval for commercially manufactured GP2 in the FLAMINGO-01 trial. This represents a transition from clinical-stage manufacturing…
EXPLORE OTHER FILTERS